Member Since 2022
Oakland CA Area
Connor Landgraf is the co-founder and CEO of Eko. Connor founded Eko while studying bioengineering at the University of California, Berkeley, with the goal of improving cardiovascular and pulmonary disease monitoring through machine learning and non-invasive sensors. Eko became the youngest team to receive FDA clearance for a medical device, and Eko technology is used by hundreds of thousands of clinicians to more effectively screen millions of patients around the world for cardiac and pulmonary disease, in-person and through telehealth. Since its founding, Eko has built the world’s largest database for heart sounds and is putting disease detection capabilities with performance comparable to that of an expert cardiologist in any clinician’s stethoscope. Connor was listed as a Forbes 30 under 30 in 2015.
We have screening guidelines for diseases like breast and colon cancer, and they help save many lives. We need a concerted effort to pursue an evidence-guided path for cardiovascular disease screening.
Eko is a digital health company advancing how healthcare professionals detect and monitor heart and lung disease with its suite of AI-powered digital tools. Its FDA-cleared technology is used by hundreds of thousands of healthcare professionals worldwide, allowing them to detect disease earlier and with higher accuracy, diagnose with more confidence, manage treatment effectively, and ultimately give their patients the best care possible. Eko is headquartered in Oakland, California, with over $125 million in funding from Highland Capital Partners, Questa Capital, Artis Ventures, DigiTx Partners, NTTVC, Morningside Technology Ventures Limited, Mayo Clinic, Sutter Health, and others. Eko exists to ensure all patients have access to early heart and lung disease detection that improves and extends their lives.